Vericel Corporation
VCELDrugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How VCEL's past catalysts played out
MACI
Chondral Defect
autologous cultured chondrocytes on porcine collagen membrane
Articular Cartilage Defect
ixmyelocel-T
Ischemic Dilated Cardiomyopathy (IDCM)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MACI | Phase 3 | Chondral Defect | - | - |
autologous cultured chondrocytes on porcine collagen membrane | Phase 3 | Articular Cartilage Defect | - | - |
ixmyelocel-T | Phase 3 | Ischemic Dilated Cardiomyopathy (IDCM) | - | - |
Chondral Defect
1 drug in this indication
Articular Cartilage Defect
1 drug in this indication
Ischemic Dilated Cardiomyopathy (IDCM)
1 drug in this indication
Peripheral Arterial Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Vericel Corporation's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Vericel Corporation's (VCEL) pipeline across Phase 3. Its lead program is MACI (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Vericel Corporation's next FDA catalyst?→
Vericel Corporation's (VCEL) next tracked catalyst is a Earnings expected July 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VCEL biotech catalysts?→
Add VCEL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vericel Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.